Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: Results of phase III trial ETV-027.

被引：0
|
作者：
Shouval, D
Lai, CL
Cheinquer, H
Lok, A
DeHertogh, D
Wilber, R
Cross, A
Zink, R
Fernandes, L
机构：
[1] Hadassah Hebrew Univ Hosp, Jerusalem, Israel
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Univ Fed Rio Grande Sul, Porto Alegre, RS, Brazil
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Univ Connecticut, Farmington, CT USA
[6] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：728A / 728A
页数：1
相关论文
共 50 条
  • [1] Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: Results of phase III study ETV-022 in nucleoside-naive patients
    Chang, TT
    Gish, R
    de Man, R
    Gadano, A
    Sollano, J
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    Dehertogh, D
    Apelian, D
    HEPATOLOGY, 2004, 40 (04) : 193A - 193A
  • [2] Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of Phase III study ETV-022 in nucleoside-naive patients
    Chang, TT
    Gish, R
    de Man, R
    Gadano, A
    Sollano, J
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    DeHertogh, D
    Apelian, D
    ANTIVIRAL THERAPY, 2004, 9 (06) : H21 - H22
  • [3] Entecavir (ETV) is superior to lamivudine (LVD) for the treatment of chronic hepatitis B (CHB): results of a phase 3 Chinese study (ETV-023) in nucleoside-naive patients
    Yao, Guangbi
    Chen, Chengwei
    Lu, Weilun
    Ren, Hong
    Tan, Deming
    Wang, Yuming
    Xu, Daozheng
    Liu, Jessica
    Xu, Dong
    Macdonald, Laurie
    Jiang, Michael
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A126 - A126
  • [4] Entecavir is superior to lamivudine for the treatment of chronic hepatitis B (CHB): Results of a phase 3 Chinese study (ETV-023) in nucleoside-naive patients
    Yao, G.
    Chen, C.
    Lu, W.
    Ren, H.
    Tan, D.
    Wang, Y.
    Xu, D.
    Jiang, M.
    Liu, J.
    Xu, D.
    MacDonald, L.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S193 - S193
  • [5] Entecavir (ETV) is well tolerated for the treatment of nucleoside-naive and Lamivudine-refractory chronic hepatitis B: phase 2/3 safety results
    Gigi, M. R.
    Manns, M.
    Cooney, E.
    Hindes, R.
    Cross, A.
    Wilber, R.
    LIVER INTERNATIONAL, 2006, 26 : 56 - 56
  • [6] FIVE YEARS OF CONTINUOUS ENTECAVIR FOR NUCLEOSIDE-NAiVE HBEAG(+) CHRONIC HEPATITIS B: RESULTS FROM STUDY ETV-901
    Han, Steven-Huy B.
    Chang, Ting-Tsung
    Chao, You-Chen
    Yoon, Seung Kew
    Gish, Robert G.
    Cheinquer, Hugo
    Kitis, George E.
    Zhang, Hui
    Iloeje, Uchenna
    HEPATOLOGY, 2008, 48 (04) : 705A - 706A
  • [7] Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: phase II/III safety results
    Gigi, M. Raptopoulou
    Manns, M.
    Cooney, E.
    Hindes, R.
    Cross, A.
    Wilber, R.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S95 - S95
  • [8] Entecavir achieves superior virologic response compared to lamivudine for the treatment of chronic hepatitis B: 2-year results from a phase 3 study in nucleoside-naive patients in China (ETV-023)
    Yao, Guangbi
    Chen, ChengWei
    Lu, WeiLun
    Ren, Hong
    Tan, DeMing
    Wang, YuMing
    Xu, DaoZheng
    Liu, Jessica
    Xu, Dong
    MacDonald, Laurie
    HEPATOLOGY, 2006, 44 (04) : 559A - 560A
  • [9] Entecavir demonstrates consistent responses among baseline subgroups in the treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B
    Brown, RS
    Lok, AS
    Gish, RG
    Schiff, ER
    Shouval, D
    Senturk, H
    Chang, TT
    Yurdaydin, C
    Apelian, D
    Fernandes, L
    Klesczewski, K
    Cross, AP
    Wilber, RB
    GASTROENTEROLOGY, 2005, 128 (04) : A737 - A738
  • [10] Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
    Chang, T. -T.
    Chao, Y. -C.
    Gorbakov, V. V.
    Han, K. -H.
    Gish, R. G.
    de Man, R.
    Cheinquer, H.
    Bessone, F.
    Brett-Smith, H.
    Tamez, R.
    JOURNAL OF VIRAL HEPATITIS, 2009, 16 (11) : 784 - 789
12345